The contemporary role and impact of urine-based biomarkers in bladder cancer
- PMID: 29354490
- PMCID: PMC5760376
- DOI: 10.21037/tau.2017.11.29
The contemporary role and impact of urine-based biomarkers in bladder cancer
Abstract
Despite advances in the surgical and medical treatment of bladder cancer, there have only been minor improvements in mortality and morbidity rates over the past decades. Urine-based markers help to improve diagnosing bladder cancer with the aim of complementing or probably in future replacing cystoscopy. Biomarkers may allow individualized risk stratification and support decision-making regarding therapy and follow-up. This review summarizes the existing urine-based biomarkers in bladder cancer. We conducted a comprehensive review of the literature. We conducted a PubMed/Medline based research on English language articles and selected original articles and review articles that provided both description and assessment of urinary markers at time of screening, initial diagnosis, monitoring and prognostic evaluation of urothelial bladder cancer. Our research covered studies published between 2000 and 2017. The aim of this study was to give clinicians keys to understand the existing or promising urinary markers that may become alternatives to cytology/cystoscopy pair in the near future. Many urinary markers are now available, often with superior sensitivity to cytology. Their uses have been evaluated in numerous clinical situations in addition to the time of initial diagnosis and surveillance such as cases of isolated macroscopic hematuria or atypical cytology discordant with the rest of the explorations. However, their superiority over the cytology/cystoscopy association is not demonstrated. These new markers are lacking for the most part of standardization and simplicity making their use in common practice difficult. the types and forms of these new markers are very heterogeneous among themselves and between the studies that evaluate them. Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of urine- and blood-based biomarkers into clinical decision-making will be of value for bladder cancer detection and screening in the future.
Keywords: Urothelial carcinoma; bladder cancer; detection; outcomes; screening; surveillance; urine biomarker.
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Similar articles
-
Urine markers for detection and surveillance of bladder cancer.Urol Oncol. 2014 Apr;32(3):222-9. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17. Urol Oncol. 2014. PMID: 24054865 Review.
-
Can urinary biomarkers replace cystoscopy?World J Urol. 2019 Sep;37(9):1741-1749. doi: 10.1007/s00345-018-2505-2. Epub 2018 Oct 3. World J Urol. 2019. PMID: 30283995 Review.
-
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.Eur Urol. 2011 Sep;60(3):484-92. doi: 10.1016/j.eururo.2011.05.053. Epub 2011 Jun 12. Eur Urol. 2011. PMID: 21684071 Review.
-
Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.BJU Int. 2012 Jul;110(1):84-94. doi: 10.1111/j.1464-410X.2011.10664.x. Epub 2011 Nov 28. BJU Int. 2012. PMID: 22122739
-
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Eur Urol Oncol. 2018. PMID: 31102625 Review.
Cited by
-
Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment.Int J Mol Sci. 2021 Mar 9;22(5):2744. doi: 10.3390/ijms22052744. Int J Mol Sci. 2021. PMID: 33803085 Free PMC article. Review.
-
Review of non-invasive urinary biomarkers in bladder cancer.Transl Cancer Res. 2020 Oct;9(10):6554-6564. doi: 10.21037/tcr-20-1990. Transl Cancer Res. 2020. PMID: 35117265 Free PMC article. Review.
-
Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles.Cancers (Basel). 2020 May 29;12(6):1400. doi: 10.3390/cancers12061400. Cancers (Basel). 2020. PMID: 32485907 Free PMC article. Review.
-
Molecularly-driven precision medicine for advanced bladder cancer.World J Urol. 2018 Nov;36(11):1749-1757. doi: 10.1007/s00345-018-2354-z. Epub 2018 Jun 8. World J Urol. 2018. PMID: 29948043 Review.
-
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.Cancers (Basel). 2021 May 31;13(11):2719. doi: 10.3390/cancers13112719. Cancers (Basel). 2021. PMID: 34072826 Free PMC article. Review.
References
-
- He D, Zeng C, Brinkley BR. Nuclear matrix proteins as structural and functional components of the mitotic apparatus. Int Rev Cytol 1995;162B:1-74. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous